FVC Reddit Mentions | ChartExchange

Vicore Pharma ($VICO SS, $VCRE US) — an asymmetric buy case into the Phase 2b IPF readout
TL;DR
Vicore is developing buloxibutid, a first-in-class ORAL AT2R agonist for idiopathic pulmonary fibrosis (IPF) — a fatal orphan disease with a large, under-treated market. The data so far point to a potentially more effective and far better-tolerated therapy than today's standard of care. The whole case is decided by one binary catalyst: the Phase 2b ASPIRE trial, topline ~mid-2027. I land on a fair value of ~SEK 40 (stock ~SEK 15.68 → +150%), with downside anchored at ~SEK 5 (net cash) if the trial fails. Heavily asymmetric risk/reward. NOT financial advice — do your own research.
THE CASE
IPF is an incurable, scarring lung disease. Median survival ~2–3 years from diagnosis — worse than many cancers. The approved drugs today only SLOW the decline, have harsh side effects (diarrhea in ~60% for nintedanib), and ~50–65% of patients discontinue.
Buloxibutid works via a different mechanism — it activates the protective arm of the renin–angiotensin system (the AT2 receptor) on the lung's repair cells (AEC2). Instead of just slowing fibrosis, it aims to REPAIR the tissue. Tolerability in Phase 2a was clean (no treatment-related serious adverse events; main issue: reversible hair loss).
Four pillars of the thesis:
1) Novel, independently validated mechanism — distinct from all the downstream targets that have failed in IPF.
2) Tolerability → persistence → revenue. Nintedanib makes billions DESPITE its toxicity and short time-on-drug. A well-tolerated, disease-modifying pill = patients stay on longer = bigger treated pool + premium price.
3) Premium pricing. A drug that IMPROVES lung function (not just slows) justifies a clear premium to standard of care.
4) Near-term catalyst + clear exit. ASPIRE is registrational-scale (~360 patients, 52-week FVC endpoint). A positive readout is heavily de-risking, and the realistic value-crystallization path is an acquisition — big pharma has repeatedly paid multiples of Vicore's current value for IPF assets.
THE MARKET — large, fatal, under-treated
- Prevalence (US): ~45,000–150,000 patients
- Median survival: ~2–3 years from diagnosis
- On antifibrotics (real-world): only 9–29%
- Discontinuation rate: 47–66%
- IPF market: ~$4.2bn today → ~$9–10bn early 2030s
The point: a fatal disease where only a minority are treated — and most who start soon stop because of side effects. Tolerability is the wedge to both broaden treatment and extend persistence.
THE CLINICAL DATA (and a big apples-to-oranges warning)
Phase 2a (AIR) was open-label, single-arm, safety-primary. Its FVC numbers are ABSOLUTE change from baseline — there was NO placebo arm. That matters: untreated IPF patients typically DECLINE ~150–200 mL/year, so an "absolute" change already includes the decline the drug is fighting.
AIR (buloxibutid), FVC at week 36:
- Headline (completer, non-imputed): +216 mL — absolute, uncontrolled, ~48% dropout, wide CI
- Pre-specified conservative (imputed): +9.4 mL — absolute, uncontrolled, CI crosses zero
- vs a synthetic/external control (imputed): ~+138 mL — NOT randomized, weak proxy only
WARNING: these CANNOT be compared directly with the controlled competitors, whose numbers are PLACEBO-ADJUSTED (drug minus placebo) from randomized Phase 3s:
- Nintedanib: +94–125 mL (placebo-adjusted)
- Nerandomilast: +69 mL (placebo-adjusted)
Being explicit: putting AIR's absolute +216 (or +9.4) mL next to a competitor's placebo-adjusted +69 mL is NOT like-for-like — I'm flagging it rather than glossing over it. AIR has no placebo arm, so no true placebo-adjusted number exists for buloxibutid yet. The +216 mL headline is NOT a "3x nerandomilast" number.
My read: the signal is real but fragile — consistent with at least stabilization, but the magnitude is uncertain. The only figure that will be truly comparable is ASPIRE's placebo-adjusted result in 2027 — which is exactly why the randomized trial is the whole thing.
ASPIRE — the catalyst (mid-2027)
- Randomized, double-blind, placebo-controlled, ~360 patients, 52-week FVC (registrational endpoint).
- As large as a Phase 3 → a positive readout materially raises the probability of approval and may open a faster path.
- Outcome distribution (my estimate): ~45% "win" / ~35% clean "fail" / ~20% ambiguous middle.
VALUATION — how I get to fair value
I use a risk-adjusted DCF (rNPV) with a premium peak-sales assumption (~$4–5bn at best-in-class pricing + persistence), and set the target as the PROBABILITY-WEIGHTED average across the ASPIRE outcomes. Downside is anchored at net cash.
- Clear win (25%): ~SEK 95
- Modest win (20%): ~SEK 53
- Ambiguous / borderline (20%): ~SEK 16
- Fail → net cash (35%): ~SEK 5
=> Probability-weighted fair value ≈ SEK 40
Calculation: 0.25×95 + 0.20×53 + 0.20×16 + 0.35×5 ≈ SEK 40
- Downside: ~SEK 5 (net cash) on failure — a hard, empirically-observed floor.
- Upside beyond the target: on a clean win the stock re-rates toward SEK 53–95 on fundamentals, and an acquisition could reach ~SEK 150–190+. (Reference: Roche bought InterMune for $8.3bn in 2014 — for a WORSE IPF drug.)
The core point: the target is not a prediction of the price in 12 months — it's a probability-weighted value over a BINARY outcome. The stock is far more likely to end up near ~SEK 5 (fail) or ~SEK 53–95 (win). The scenario ladder is what matters.
WHAT MUST BE TRUE
1) ASPIRE shows a statistically significant, placebo-adjusted FVC benefit at 52 weeks.
2) The benefit holds on top of nintedanib (add-on).
3) Tolerability replicates under blinding (incl. manageable hair loss).
4) Premium pricing is achievable.
THE RISKS (read these — this is a high-risk case)
- Clinical failure in ASPIRE is the dominant risk → stock toward ~SEK 5. IPF is a drug graveyard (pamrevlumab, ziritaxestat, GB0139, bexotegrast — all failed).
- Underpowering: with a modest effect and high variance, the trial could miss significance even if the drug works.
- Pricing/reimbursement could come in below assumptions (the single largest value driver).
- Financing/dilution: Phase 3 is not yet funded.
- Single asset — no diversification. Size for a binary.
CONCLUSION
A genuinely asymmetric case: anchored downside (~SEK 5), multiplicative upside (SEK 53–95 on a win, more on a takeout), a near-term catalyst (ASPIRE mid-2027), and a credible exit. The market appears to under-price both the quality of the mechanism and the persistence upside. Fair value ~SEK 40. But the whole case is decided by ASPIRE. Size the position for a binary outcome.
Charts in the comments: 1) scenario ladder & target, 2) price × probability sensitivity, 3) probability-of-success hierarchy, 4) AIR data (headline vs conservative).
Disclaimer: Not financial advice and not a buy/sell recommendation. My own analysis of public sources (clinical registries, peer-reviewed literature, company reports). Clinical outcomes are uncertain; you can lose your entire stake in a binary biotech. DYOR. Position: I'm long!